Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | STRO-002 |
Synonyms | |
Therapy Description |
STRO-002 is an antibody-drug conjugate that consists of an anti-FolRa human IgG1 antibody linked to the anti-tubulin agent 3-aminophenyl hemiasterlin (SC209), which may inhibit growth of FolRa expressing tumors (Cancer Res 2018;78(13 Suppl):Abstract nr 1782). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
STRO-002 | STRO002 | STRO-002 is an antibody-drug conjugate that consists of an anti-FolRa human IgG1 antibody linked to the anti-tubulin agent 3-aminophenyl hemiasterlin (SC209), which may inhibit growth of FolRa expressing tumors (Cancer Res 2018;78(13 Suppl):Abstract nr 1782). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03748186 | Phase I | STRO-002 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolR?) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | Recruiting | USA | ESP | 0 |